US 8895018
Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
granted A61KA61K2039/605A61K39/0007
Quick answer
US patent 8895018 (Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction) held by The United States of America as represented by the Department of Veteran Affairs expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as represented by the Department of Veteran Affairs
- Grant date
- Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K2039/605, A61K39/0007, A61K39/0013, A61K45/06